Luke Sergott
Stock Analyst at Barclays
(2.21)
# 2,830
Out of 5,245 analysts
413
Total ratings
39.8%
Success rate
-3.52%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CERT Certara | Maintains: Equal-Weight | $8 → $6.5 | $5.24 | +24.05% | 23 | May 12, 2026 | |
| PACB Pacific Biosciences of California | Maintains: Underweight | $1 → $1.5 | $1.22 | +22.95% | 9 | May 11, 2026 | |
| GH Guardant Health | Maintains: Overweight | $115 → $120 | $118.95 | +0.88% | 8 | May 8, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $210 → $220 | $160.30 | +37.24% | 14 | May 8, 2026 | |
| WAT Waters | Maintains: Overweight | $400 → $425 | $342.37 | +24.13% | 20 | May 7, 2026 | |
| RVTY Revvity | Maintains: Equal-Weight | $95 → $105 | $96.95 | +8.30% | 15 | May 7, 2026 | |
| BRKR Bruker | Maintains: Overweight | $45 → $53 | $45.69 | +16.00% | 12 | May 7, 2026 | |
| RGEN Repligen | Maintains: Overweight | $145 → $160 | $115.06 | +39.06% | 7 | May 6, 2026 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $11 → $16 | $13.22 | +21.03% | 17 | May 6, 2026 | |
| TWST Twist Bioscience | Maintains: Overweight | $55 → $65 | $60.57 | +7.31% | 23 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $122 | $144.41 | -15.52% | 23 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $44 → $38 | $35.17 | +8.05% | 5 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $275 → $310 | $316.42 | -2.03% | 7 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $500 → $450 | $432.80 | +3.97% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $230 | $195.21 | +17.82% | 1 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8.5 → $7 | $8.12 | -13.79% | 30 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $30 | $23.68 | +26.69% | 16 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $140 | $114.96 | +21.78% | 16 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $230 | $172.00 | +33.72% | 42 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,550 → $1,500 | $1,103.09 | +35.98% | 5 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $18 | $15.71 | +14.61% | 24 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $625 | $448.28 | +39.42% | 31 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $200 → $120 | $116.78 | +2.76% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $210 | $167.90 | +25.07% | 26 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $203.19 | +32.88% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $97.16 | -7.37% | 1 | Aug 1, 2025 |
Certara
May 12, 2026
Maintains: Equal-Weight
Price Target: $8 → $6.5
Current: $5.24
Upside: +24.05%
Pacific Biosciences of California
May 11, 2026
Maintains: Underweight
Price Target: $1 → $1.5
Current: $1.22
Upside: +22.95%
Guardant Health
May 8, 2026
Maintains: Overweight
Price Target: $115 → $120
Current: $118.95
Upside: +0.88%
Charles River Laboratories International
May 8, 2026
Maintains: Overweight
Price Target: $210 → $220
Current: $160.30
Upside: +37.24%
Waters
May 7, 2026
Maintains: Overweight
Price Target: $400 → $425
Current: $342.37
Upside: +24.13%
Revvity
May 7, 2026
Maintains: Equal-Weight
Price Target: $95 → $105
Current: $96.95
Upside: +8.30%
Bruker
May 7, 2026
Maintains: Overweight
Price Target: $45 → $53
Current: $45.69
Upside: +16.00%
Repligen
May 6, 2026
Maintains: Overweight
Price Target: $145 → $160
Current: $115.06
Upside: +39.06%
Fortrea Holdings
May 6, 2026
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $13.22
Upside: +21.03%
Twist Bioscience
May 5, 2026
Maintains: Overweight
Price Target: $55 → $65
Current: $60.57
Upside: +7.31%
May 1, 2026
Maintains: Underweight
Price Target: $110 → $122
Current: $144.41
Upside: -15.52%
Apr 29, 2026
Maintains: Equal-Weight
Price Target: $44 → $38
Current: $35.17
Upside: +8.05%
Apr 27, 2026
Maintains: Equal-Weight
Price Target: $275 → $310
Current: $316.42
Upside: -2.03%
Apr 24, 2026
Maintains: Equal-Weight
Price Target: $500 → $450
Current: $432.80
Upside: +3.97%
Apr 22, 2026
Maintains: Overweight
Price Target: $225 → $230
Current: $195.21
Upside: +17.82%
Apr 15, 2026
Maintains: Underweight
Price Target: $8.5 → $7
Current: $8.12
Upside: -13.79%
Apr 14, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $23.68
Upside: +26.69%
Apr 14, 2026
Maintains: Overweight
Price Target: $150 → $140
Current: $114.96
Upside: +21.78%
Apr 14, 2026
Maintains: Overweight
Price Target: $250 → $230
Current: $172.00
Upside: +33.72%
Apr 14, 2026
Maintains: Overweight
Price Target: $1,550 → $1,500
Current: $1,103.09
Upside: +35.98%
Apr 14, 2026
Maintains: Overweight
Price Target: $20 → $18
Current: $15.71
Upside: +14.61%
Apr 14, 2026
Maintains: Overweight
Price Target: $650 → $625
Current: $448.28
Upside: +39.42%
Mar 9, 2026
Maintains: Equal-Weight
Price Target: $200 → $120
Current: $116.78
Upside: +2.76%
Mar 6, 2026
Upgrades: Overweight
Price Target: $210
Current: $167.90
Upside: +25.07%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $203.19
Upside: +32.88%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $97.16
Upside: -7.37%